Biomarker Discovery

HuProt for the Identification of Important Biomarkers

Providing highly valuable insights into human disease

Autoantibodies serve as valuable biomarkers for a wide range of diseases and conditions, including autoimmune disorders, infectious diseases, cancer, and neurological disorders. As biomarkers, autoantibodies offer several advantages, including their specificity, accessibility, and potential for early detection. The identification of autoantibody biomarkers or signatures can provide researchers with highly valuable information relevant to many aspects of human disease, including disease mechanisms, diagnostic information, disease classification, prediction of therapy response and likelihood of adverse treatment reactions.

In the featured publication below, HuProt™ microarrays were used to identify 501 candidate biomarkers differentially expressed in a training cohort (p>0.01). From these findings, 20 autoantibodies were selected for further analysis: CFAP36, DCD, DR1, GPBP1, HNRNPD, IKZF5, KEAP1, MED21, MIDIP1, MYBPH, NAP1L5, NAT9, NIP30, PJA2, PNMA1, RAB27A, SGPL1, TAF10, Ubiquillin 2, ZNF696. The publication concluded that novel circulating autoantibodies may have the potential to select patients with actionable lesions on lung cancer screening low-dose computed tomography scans.

Featured Publication

Serum Autoantibodies may help Identify Individuals with Actionable Pulmonary Nodules on LDCT Scan

C. Auger, H. Moudgalya, P. Shah, M. Liptay, C. Seder, J. Borgia

Background

Blood-based biomarkers can serve as a simple and cost-effective method, when used in conjunction with USPSTF guidelines, for selecting LDCT screening. Due to B-cell amplification, autoantibodies are found at a higher concentration in blood than their corresponding neoantigens, making them potentially valuable as early detection biomarkers. We hypothesize, circulating autoantibody targets can be utilized for ‘pre-screening’ individuals for LDCT testing.

VIEW PAPER

CDI Labs Advantages

The most comprehensive protein collections available allow for rapid proteome wide antibody repertoire analysis and target identification studies.

HuProt™ Proteome Microarrays provide high quality, reproducible results with a protein purification process that only selects properly folded proteins.

GMP/GLP compliant workflows and highly trained technicians ensure the highest quality results. Compliant data management processes ensure data integrity and security.

Cutting-edge synthetic biology platforms and an innovative team with deep proteomics bench expertise make CDI Labs an ideal CRO partner for even your most challenging projects.

HuProt Sample Requirements

Human serum or plasma

One 20 μL per sample

Antibody isolates

10 μg per sample (concentration 0.1 mg/mL)

Human cerebrospinal fluid (CSF)

Minimum 1.5 mL per sample

Protein / peptide / small molecule

10 μg per sample (concentration 0.1 mg/mL)

RNA

1 mL per sample (concentration 2 μM)

Other fluids

> Please contact us